1-deoxynojirimycin has been researched along with Body Weight in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (16.67) | 18.7374 |
| 1990's | 6 (25.00) | 18.2507 |
| 2000's | 7 (29.17) | 29.6817 |
| 2010's | 7 (29.17) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Eitsuka, T; Ikeda, R; Ito, J; Kimura, T; Miyazawa, T; Nakagawa, K; Parida, IS; Takasu, S; Yamagishi, K | 1 |
| Chung, JH; Do, HJ; Hwang, JW; Kim, OY; Lee, JY; Shin, MJ | 1 |
| Barnard, DL; Callahan, MV; Day, CW; Enterlein, SG; Khaliq, M; Ramstedt, U; Sampath, A; Smee, DF; Warfield, KL | 1 |
| Grittner, U; Holzmann, C; Rolfs, A; Schlegel, V; Thieme, M; Witt, M; Wree, A | 1 |
| Baek, RC; Bronson, RT; Butters, TD; Denny, CA; Heinecke, KA; Kim, YP; Loh, KS; Platt, FM; Seyfried, TN | 1 |
| Aerts, JM; Bijl, N; Bijland, S; Groen, AK; Houben-Weerts, JH; Houten, SM; Langeveld, M; Ottenhoff, R; Romijn, JA; van den Berg, SA; van Dijk, KW; van Roomen, CP; Voshol, PJ | 1 |
| Bhatia, G; Chaturvedi, U; Saxena, JK; Shrivastava, A; Singh, SV | 1 |
| D'Azzo, A; El-Abbadi, MM; Hauser, EC; Kasperzyk, JL; Platt, FM; Seyfried, TN | 1 |
| Aerts, JM; Boon, L; Bullens, D; Ceuppens, JL; Geboes, K; Kasran, A; Maerten, P; Rutgeerts, P; Shen, C; Van Assche, G | 1 |
| Andersson, U; Borja, MC; Butters, TD; Dwek, RA; Jeyakumar, M; Platt, FM; Smith, D | 1 |
| Fehmann, HC | 2 |
| Barnett, NL; Kolodny, EH; Pastores, GM | 1 |
| DeBouno, JF; Michaelis, OE; Tulp, OL | 1 |
| Butters, TD; Dwek, RA; Platt, FM; Reinkensmeier, G | 1 |
| Chiasson, JL; Rabasa-Lhoret, R | 1 |
| Dolphin, PJ; Graham, SE; Russell, JC | 1 |
| El-Abbadi, M; Manfredi, MG; Mukherjee, P; Platt, FM; Ranes, MK; Seyfried, TN | 1 |
| Holman, RR; Steemson, J; Turner, RC | 1 |
| Atsumi, S; Iinuma, H; Nosaka, C; Umezawa, K | 1 |
| Creutzfeldt, W; Fehmann, HC; Fölsch, UR; Göke, B; Siegel, EG | 1 |
| Bezerra, J; Bustamante, S; Flores, C; Goda, T; Koldovský, O; Lee, SM | 1 |
| Gerard, J; Hillebrand, I; Lefèbvre, PJ | 1 |
| Madar, Z; Olefsky, J | 1 |
1 review(s) available for 1-deoxynojirimycin and Body Weight
| Article | Year |
|---|---|
Potential of alpha-glucosidase inhibitors in elderly patients with diabetes mellitus and impaired glucose tolerance.
Topics: 1-Deoxynojirimycin; Acarbose; Aged; Body Weight; Cognition; Diabetes Mellitus, Type 2; Enzyme Inhibitors; Glucosamine; Glucose Intolerance; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Imino Pyranoses; Trisaccharides | 1998 |
3 trial(s) available for 1-deoxynojirimycin and Body Weight
| Article | Year |
|---|---|
An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment.
Topics: 1-Deoxynojirimycin; Adult; Blood; Body Weight; Drug Tolerance; Enzyme Inhibitors; Female; Gaucher Disease; Humans; Liver; Male; Middle Aged; Spleen; Treatment Outcome | 2005 |
Post-prandial glycaemic reduction by an alpha-glucosidase inhibitor in type 2 diabetic patients with therapeutically attained basal normoglycaemia.
Topics: 1-Deoxynojirimycin; Biomarkers; Blood Glucose; Body Weight; Diabetes Mellitus, Type 2; Diet, Diabetic; Eating; Female; Fructosamine; Glucosamine; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Hexosamines; Humans; Hypoglycemic Agents; Imino Pyranoses; Insulin; Insulin, Long-Acting; Lipoproteins, HDL; Lipoproteins, LDL; Male; Middle Aged; Reference Values; Time Factors; Triglycerides | 1991 |
Assessment of the clinical efficacy and tolerance of two new alpha-glucosidase inhibitors in insulin-treated diabetics.
Topics: 1-Deoxynojirimycin; Adult; Blood Glucose; Body Weight; Diabetes Mellitus; Drug Tolerance; Fatty Acids, Nonesterified; Female; Glucosamine; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Imino Pyranoses; Insulin; Male; Middle Aged | 1987 |
20 other study(ies) available for 1-deoxynojirimycin and Body Weight
| Article | Year |
|---|---|
Physiological Effects and Organ Distribution of Bacillus amyloliquefaciens AS385 Culture Broth Powder Containing 1-Deoxynojirimycin in C57BL/6J Mice.
Topics: 1-Deoxynojirimycin; Animals; Bacillus amyloliquefaciens; Blood Glucose; Body Weight; Culture Media; Insulin; Male; Mice; Mice, Inbred C57BL; Powders; Tissue Distribution | 2019 |
1-deoxynojirimycin isolated from Bacillus subtilis improves hepatic lipid metabolism and mitochondrial function in high-fat-fed mice.
Topics: 1-Deoxynojirimycin; Acetyl-CoA Carboxylase; Adipose Tissue; AMP-Activated Protein Kinases; Animals; Anti-Obesity Agents; Bacillus subtilis; Body Weight; CCAAT-Enhancer-Binding Proteins; CD36 Antigens; Diet, High-Fat; Dietary Supplements; Energy Intake; Fatty Acid Synthases; Lipid Metabolism; Liver; Male; Mice; Mice, Inbred C57BL; Mitochondria, Liver; Obesity; Organ Size; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha; Phosphorylation; Transcription Factors | 2015 |
The Iminosugar UV-4 is a Broad Inhibitor of Influenza A and B Viruses ex Vivo and in Mice.
Topics: 1-Deoxynojirimycin; Animals; Antiviral Agents; Body Weight; Cells, Cultured; Disease Models, Animal; Epithelial Cells; Humans; Influenza A virus; Influenza B virus; Mice; Orthomyxoviridae Infections; Survival Analysis; Treatment Outcome | 2016 |
Pharmacologic Treatment Assigned for Niemann Pick Type C1 Disease Partly Changes Behavioral Traits in Wild-Type Mice.
Topics: 1-Deoxynojirimycin; Animals; Behavior, Animal; Body Weight; Brain; Cognition; Cyclodextrins; Disease Models, Animal; Drug Administration Schedule; Drug Combinations; Hypolipidemic Agents; Male; Maze Learning; Mice; Mice, Inbred BALB C; Niemann-Pick Disease, Type C; Organ Size; Pregnanolone | 2016 |
Restricted ketogenic diet enhances the therapeutic action of N-butyldeoxynojirimycin towards brain GM2 accumulation in adult Sandhoff disease mice.
Topics: 1-Deoxynojirimycin; 3-Hydroxybutyric Acid; Analysis of Variance; Animals; beta-N-Acetylhexosaminidases; Blood Glucose; Body Weight; Brain; Chromatography, High Pressure Liquid; Chromatography, Thin Layer; Diet, Ketogenic; Eating; G(M2) Ganglioside; Lipid Metabolism; Mice; Mice, Knockout; Myelin Sheath; Purkinje Cells; Sandhoff Disease | 2010 |
Treatment of genetically obese mice with the iminosugar N-(5-adamantane-1-yl-methoxy-pentyl)-deoxynojirimycin reduces body weight by decreasing food intake and increasing fat oxidation.
Topics: 1-Deoxynojirimycin; Adamantane; Adipose Tissue; Animals; Body Weight; Carbohydrate Metabolism; Carnitine O-Palmitoyltransferase; Eating; Ghrelin; Glucose; Imino Sugars; Liver; Mice; Mice, Inbred C57BL; Mice, Obese; Obesity; Oxidation-Reduction; Peptide YY; Triglycerides; Up-Regulation; Weight Gain | 2012 |
Lipid lowering and antioxidant effect of miglitol in triton treated hyperlipidemic and high fat diet induced obese rats.
Topics: 1-Deoxynojirimycin; 3T3-L1 Cells; Adipogenesis; Animals; Antioxidants; Body Weight; Diet, High-Fat; Eating; Hyperlipidemias; Hypoglycemic Agents; Lipids; Liver; Male; Mice; Obesity; Polyethylene Glycols; Rats | 2013 |
N-butyldeoxygalactonojirimycin reduces neonatal brain ganglioside content in a mouse model of GM1 gangliosidosis.
Topics: 1-Deoxynojirimycin; Animals; Animals, Newborn; Body Weight; Brain; Brain Chemistry; Chromatography, Thin Layer; Disease Models, Animal; Fetal Viability; Gangliosides; Gangliosidosis, GM1; Lipid Metabolism; Lipids; Mice; Mice, Inbred C57BL; Mice, Knockout; Treatment Outcome | 2004 |
Inhibition of glycolipid biosynthesis by N-(5-adamantane-1-yl-methoxy-pentyl)-deoxynojirimycin protects against the inflammatory response in hapten-induced colitis.
Topics: 1-Deoxynojirimycin; Adamantane; Animals; Anti-Inflammatory Agents; Antibodies; Body Weight; Colitis; Colon; Disease Models, Animal; Enzyme Inhibitors; Glycolipids; Haptens; Immunoglobulin G; Immunosuppressive Agents; Interferon-gamma; Interleukin-18; Male; Mice; Mice, Inbred C57BL; Oxazolone; Peroxidase; Trinitrobenzenesulfonic Acid | 2004 |
Improved outcome of N-butyldeoxygalactonojirimycin-mediated substrate reduction therapy in a mouse model of Sandhoff disease.
Topics: 1-Deoxynojirimycin; Animals; Behavior, Animal; beta-N-Acetylhexosaminidases; Body Weight; Brain; Disease Models, Animal; Female; Gangliosides; Life Expectancy; Liver; Male; Mice; Mice, Mutant Strains; Sandhoff Disease | 2004 |
[The alpha-glucosidase inhibitor miglitol for the treatment of type 2 diabetes mellitus in the doctor's office].
Topics: 1-Deoxynojirimycin; Adult; Aged; Aged, 80 and over; Blood Glucose; Body Mass Index; Body Weight; Diabetes Mellitus, Type 2; Female; Glucosamine; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Imino Pyranoses; Male; Middle Aged; Safety; Time Factors; Triglycerides | 2001 |
The effects of the intestinal glucosidase inhibitory BAY M 1099 (miglitol) on glycemic status of obese-diabetic rats.
Topics: 1-Deoxynojirimycin; Animals; Blood Glucose; Body Weight; Diabetes Mellitus; Diabetes Mellitus, Type 2; Eating; Glucosamine; Glycoside Hydrolase Inhibitors; Imino Pyranoses; Male; Obesity; Rats; Rats, Inbred SHR | 1993 |
Extensive glycosphingolipid depletion in the liver and lymphoid organs of mice treated with N-butyldeoxynojirimycin.
Topics: 1-Deoxynojirimycin; Animals; Body Weight; Cholera Toxin; Enzyme Inhibitors; Female; Glucosyltransferases; Glycosphingolipids; Immunophenotyping; Liver; Lymphoid Tissue; Mice; Mice, Inbred C57BL | 1997 |
Glucose tolerance and insulin resistance in the JCR:LA-corpulent rat: effect of miglitol (Bay m1099).
Topics: 1-Deoxynojirimycin; Animals; Blood Glucose; Body Weight; Disease Models, Animal; Eating; Enzyme Inhibitors; Glucosamine; Glucose Tolerance Test; Glycoside Hydrolase Inhibitors; Hypoglycemic Agents; Imino Pyranoses; Insulin; Insulin Resistance; Lipids; Male; Obesity; Postprandial Period; Rats | 1999 |
N -butyldeoxynojirimycin reduces growth and ganglioside content of experimental mouse brain tumours.
Topics: 1-Deoxynojirimycin; Animals; Body Weight; Brain; Brain Neoplasms; Cell Count; Cell Division; Gangliosides; Intestines; Liver; Male; Methylcholanthrene; Mice; Mice, Inbred C57BL; Time Factors; Tissue Distribution; Tumor Cells, Cultured | 2001 |
[Alpha-glucosidase inhibitor in type 2 diabetic patients. Metabolism and body weight are favorably modified].
Topics: 1-Deoxynojirimycin; Body Weight; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Drug Administration Schedule; Energy Metabolism; Glucosamine; Glycated Hemoglobin; Glycoside Hydrolase Inhibitors; Humans; Hypoglycemic Agents; Imino Pyranoses | 2001 |
Biological activities of cyclophellitol.
Topics: 1-Deoxynojirimycin; Animals; Anti-Bacterial Agents; beta-Glucosidase; Binding, Competitive; Body Weight; Cell Line; Cyclohexanols; Female; Glucosamine; Glucosylceramidase; Indolizines; Mice; Microsomes; Tumor Cells, Cultured | 1990 |
Influence of an absorbable alpha-glucosidase inhibitor (Bay o 1248) on the endocrine and exocrine pancreas of the rat.
Topics: 1-Deoxynojirimycin; Amylases; Animals; Body Weight; Glucosamine; Glycoside Hydrolase Inhibitors; Insulin; Islets of Langerhans; Male; Pancreas; Rats; Rats, Inbred Strains; Trypsin | 1986 |
Chronic effects of an alpha-glucosidase inhibitor (Bay o 1248) on intestinal disaccharidase activity in normal and diabetic mice.
Topics: 1-Deoxynojirimycin; alpha-Glucosidases; Animals; beta-Galactosidase; Body Weight; Diabetes Mellitus, Experimental; Disaccharidases; Eating; Glucosamine; Glycoside Hydrolase Inhibitors; Intestine, Small; Mice; Mice, Inbred C57BL; Sucrase | 1987 |
Effect of the alpha-glucosidase inhibitor Bay-O-1248 on the metabolic response of nondiabetic and diabetic rats to a high-carbohydrate diet.
Topics: 1-Deoxynojirimycin; Animals; Blood Glucose; Body Weight; Cholesterol; Diabetes Mellitus, Experimental; Dietary Carbohydrates; Glucosamine; Glycosuria; Male; Rats; Rats, Inbred Strains; Triglycerides | 1986 |